Surmodics - SRDX Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surmodics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SRDX shares.
View SRDX analyst ratings or view top-rated stocks.

2 equities research analysts have issued twelve-month target prices for Surmodics' shares. Their SRDX share price forecasts range from $34.00 to $60.00. On average, they predict the company's stock price to reach $47.00 in the next twelve months. This suggests a possible upside of 144.4% from the stock's current price.
View analysts price targets for SRDX or view top-rated stocks among Wall Street analysts.

Surmodics' stock was trading at $34.12 on January 1st, 2023. Since then, SRDX shares have decreased by 43.6% and is now trading at $19.23.
View the best growth stocks for 2023 here.

Surmodics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 544,500 shares, an increase of 24.8% from the February 28th total of 436,400 shares. Based on an average trading volume of 169,200 shares, the short-interest ratio is presently 3.2 days. Approximately 4.0% of the shares of the company are short sold.
View Surmodics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023.
View our SRDX earnings forecast.

Surmodics, Inc. (NASDAQ:SRDX) released its quarterly earnings results on Monday, February, 6th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.13. The company earned $24.93 million during the quarter, compared to the consensus estimate of $24.19 million. Surmodics had a negative trailing twelve-month return on equity of 15.61% and a negative net margin of 31.71%. During the same quarter in the previous year, the business posted ($0.13) EPS.

ETFs with the largest weight of Surmodics (NASDAQ:SRDX) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Invesco S&P SmallCap Health Care ETF (PSCH), Invesco Nasdaq Future Gen 200 ETF (QQQS).iShares U.S. Medical Devices ETF (IHI) and

Surmodics updated its FY 2023 earnings guidance on Monday, February, 6th. The company provided earnings per share (EPS) guidance of -$2.09--$1.69 for the period, compared to the consensus EPS estimate of -$2.38. The company issued revenue guidance of $102.00 million-$106.00 million, compared to the consensus revenue estimate of $104.84 million.

8 employees have rated Surmodics Chief Executive Officer Gary Maharaj on Glassdoor.com. Gary Maharaj has an approval rating of 65% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Surmodics investors own include Gilead Sciences (GILD), Netflix (NFLX), Exelixis (EXEL), Intel (INTC), NVIDIA (NVDA), Tandem Diabetes Care (TNDM), uniQure (QURE), Sangamo Therapeutics (SGMO), Abbott Laboratories (ABT) and Dynavax Technologies (DVAX).

Surmodics trades on the NASDAQ under the ticker symbol "SRDX."

Surmodics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Soleus Capital Management L.P. (5.49%), Renaissance Technologies LLC (4.11%), Dimensional Fund Advisors LP (3.14%), Millennium Management LLC (1.98%), Geode Capital Management LLC (1.78%) and Charles Schwab Investment Management Inc. (0.74%). Insiders that own company stock include Charles W Olson, Charles W Olson, David Dantzker, Gary R Maharaj, Gary R Maharaj, John D Manders, Jose H Bedoya, Jose H Bedoya, Joseph J Stich, Joseph J Stich and Ronald B Sr Kalich Sr.
View institutional ownership trends.

Shares of SRDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SRDX stock can currently be purchased for approximately $19.23.

Surmodics (NASDAQ:SRDX) has a market capitalization of $271.72 million and generates $99.95 million in revenue each year. The company earns $-27,270,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis.

The company employs 389 workers across the globe.

Surmodics' mailing address is 9924 WEST 74TH STREET, EDEN PRAIRIE MN, 55344. The official website for the company is www.surmodics.com. The company can be reached via phone at (952) 500-7000, via email at ir@surmodics.com, or via fax at 952-500-7001.